Neuromyelitis optica spectrum disorder (NMOSD) is a rare, relapsing, autoimmune, inflammatory disorder that typically affects the optic nerves and spinal cord and therefore causes blindness and paralysis. NMOSD relapses can cause significant and irreversible neurologic disability. No approved therapies exist for NMOSD. However, some targeted therapies are in development and promising results recently presented or published.
Eculizumab in AQP4-IgG-positive NMOSD
At least two thirds of NMOSD cases are associated with aquaporin-4 antibodies (AQP4-IgG) and complement-mediated damage to the central nervous system. Eculizumab, a terminal complement inhibitor, reduced the risk of NMOSD relapse in patients with AQP4-IgG-positive NMOSD. In the phase 3 PREVENT trial, 143 adults were randomised to receive intravenous eculizumab or placebo. The mean annualised relapse rate (ARR) in the 2 years before enrolment was 1.99. It was permitted to cont...
please login to read the entire article:
You need to register to read the entire article, please do so now.
« Less Focus on Quality of Life in Recent Phase 3 Trials Next Article
Late-breaking: Myelin-peptide coupled red blood cells »
Table of Contents: ECTRIMS 2019
Towards a Comprehensive Assessment of MS Course
Monitoring and Treatment of Progressive MS
Optimising Long-Term Benefit of MS Treatment
Safety Assessment in the Post-Approval Phase
Pregnancy in the Treatment Era
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.